Evidence map›Paper›PMID 39779579›Full record

ArticleBiochemical genetics2026

Identification of a Novel Immune-Gene Signature with Prognostic Value in Patients with Head and Neck Cancer: A Pilot Study.

Panagiota Batsaki, Sotirios P Fortis, Angelos D Gritzapis, Andriana Razou, Athanasios C Sakellaridis, Elisavet Grouzi, Dimitra Moschandreou, Michael I Koukourakis, Vassilios Zoumpourlis, Constantin N Baxevanis and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Panagiota BatsakiCancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Sotirios P FortisCancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Angelos D GritzapisCancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Andriana RazouDepartment of Otorhinolaryngology/Head & Neck Surgery, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Athanasios C SakellaridisDepartment of Otorhinolaryngology/Head & Neck Surgery, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Elisavet GrouziDepartment of Transfusion Service and Clinical Hemostasis, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Dimitra MoschandreouDepartment of Transfusion Service and Clinical Hemostasis, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Michael I KoukourakisDepartment of Radiotherapy/Oncology, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Vassilios ZoumpourlisBiomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 11635, Athens, Greece.
Constantin N BaxevanisCancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522, Athens, Greece.
Maria GoulielmakiCancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522, Athens, Greece. mgoulielmaki@ciic.gr.

Funding

European Regional Development Fund and Greek funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research-Create-Innovate Τ2EDK-03266
6 · The paper itself

Abstract

The tumor microenvironment has a significant input on prognosis and also for predicting clinical outcomes in various types of cancers. However, tumor tissue is not always available, thus, rendering peripheral blood a preferable alternative in the search for prognostic and predictive gene signatures. Head and neck squamous cell carcinoma (HNSCC) constitutes a quite heterogeneous disease characterized by poor prognosis. Therefore, the discovery of novel therapeutics based on prognostic gene signatures for effective disease governance is of paramount importance. In this study, we report for the first time an immune-gene signature identified in the peripheral blood of HNSCC patients comprising five genes (CLEC4C, IL23A, LCK, LY9, and CD19) which were more than threefold downregulated as compared to healthy individuals and were associated with poor prognosis. By performing analyses of HNSCC tumor samples from The Cancer Genome Atlas (TCGA) database, we discovered that decreased expression of these genes, both as single genes and as a 5-gene signature (5-GS), was significantly correlated with worse overall survival (OS). Our data show that the levels of expression of the 5-GS represent an immune profile predicting OS in patients with HNSCC.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellHead and Neck NeoplasmsTranscriptomeAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPilot ProjectsPrognosisSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentBiomarkers, Tumor5-gene signatureGene expressionHead and neck cancerPeripheral bloodPrognostic biomarkerThe cancer genome atlas

Identifiers

PMID39779579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.